The main beneficiary of Roche’s discontinuation of an investigational spinal muscular atrophy drug is Scholar Rock, which was ...
Please provide your email address to receive an email when new articles are posted on . Interim results also showed reduction of the neurodegenerative biomarker neurofilament light chain. Serious ...
Please provide your email address to receive an email when new articles are posted on . The study included 58 individuals with SMA types 2 and 3 who were treated with IV apitegromab for 52 weeks. At ...
Long-term data from DEVOTE/ONWARD studies show benefits of high dose nusinersen in people living with spinal muscular atrophy (SMA) New Phase 1b data further illustrate potential of salanersen in SMA, ...
Scotland has become the first UK nation to screen all newborn babies for spinal muscular atrophy. Here is what you need to ...
Data presented at the 2026 Muscular Dystrophy Association meeting could have readthroughs to companies developing therapies ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic ...
Europe’s Committee for Medicinal Products for Human Use (CHMP) has recommended granting a conditional marketing authorization for Duvyzat (givinostat, Italfarmaco) to treat Duchenne muscular dystrophy ...
The Ironman In You project aims to raise awareness on muscular dystrophy It also aims to raise money for members of the Muscular Dystrophy Association of Singapore As of June 25, this project had ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results